459 related articles for article (PubMed ID: 16155016)
21. Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities.
Rasmussen T; Theilgaard-Mönch K; Hudlebusch HR; Lodahl M; Johnsen HE; Dahl IM
Br J Haematol; 2003 Oct; 123(2):253-62. PubMed ID: 14531906
[TBL] [Abstract][Full Text] [Related]
22. Identification of primary MAFB target genes in multiple myeloma.
van Stralen E; van de Wetering M; Agnelli L; Neri A; Clevers HC; Bast BJ
Exp Hematol; 2009 Jan; 37(1):78-86. PubMed ID: 19013005
[TBL] [Abstract][Full Text] [Related]
23. Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.
Kuroda Y; Sakai A; Tsuyama N; Katayama Y; Munemasa S; Asaoku H; Okikawa Y; Nakaju N; Mizuno M; Ogawa K; Nishisaka T; Matsui H; Tanaka H; Kimura A
Int J Oncol; 2008 Dec; 33(6):1201-13. PubMed ID: 19020753
[TBL] [Abstract][Full Text] [Related]
24. Molecular pathogenesis of multiple myeloma.
Tonon G
Hematol Oncol Clin North Am; 2007 Dec; 21(6):985-1006, vii. PubMed ID: 17996585
[TBL] [Abstract][Full Text] [Related]
25. Hyperdiploidy is a common finding in monoclonal gammopathy of undetermined significance and monosomy 13 is restricted to these hyperdiploid patients.
Brousseau M; Leleu X; Gerard J; Gastinne T; Godon A; Genevieve F; Dib M; Lai JL; Facon T; Zandecki M;
Clin Cancer Res; 2007 Oct; 13(20):6026-31. PubMed ID: 17947464
[TBL] [Abstract][Full Text] [Related]
26. Molecular Pathogenesis of Multiple Myeloma: Clinical Implications.
Maura F; Bergsagel PL
Hematol Oncol Clin North Am; 2024 Apr; 38(2):267-279. PubMed ID: 38199896
[TBL] [Abstract][Full Text] [Related]
27. Advances in biology and therapy of multiple myeloma.
Barillé-Nion S; Barlogie B; Bataille R; Bergsagel PL; Epstein J; Fenton RG; Jacobson J; Kuehl WM; Shaughnessy J; Tricot G
Hematology Am Soc Hematol Educ Program; 2003; ():248-78. PubMed ID: 14633785
[TBL] [Abstract][Full Text] [Related]
28. RAS mutations are uncommon in multiple myeloma and other monoclonal gammopathies.
Martín P; Santón A; García-Cosío M; Bellas C
Int J Oncol; 2005 Oct; 27(4):1023-8. PubMed ID: 16142319
[TBL] [Abstract][Full Text] [Related]
29. Multicolor interphase cytogenetics for the study of plasma cell dyscrasias.
Sáez B; Martín-Subero JI; Odero MD; Prosper F; Cigudosa JC; Schoch R; Calasanz MJ; Siebert R
Oncol Rep; 2007 Nov; 18(5):1099-106. PubMed ID: 17914559
[TBL] [Abstract][Full Text] [Related]
30. Chromosomal translocations t(4;14), t(11;14) and proliferation rate stratify patients with mature plasma cell myelomas into groups with different survival probabilities: a molecular epidemiologic study on tissue microarrays.
Tinguely M; Jenni B; Reineke T; Korol D; Kofler A; Rousson V; Dommann-Scherrer C; Maurer R; Moch H; Probst-Hensch NM
Am J Surg Pathol; 2007 May; 31(5):690-6. PubMed ID: 17460451
[TBL] [Abstract][Full Text] [Related]
31. Protein Expression for Novel Prognostic Markers (Cyclins D1, D2, D3, B1, B2, ITGβ7, FGFR3, PAX5) Correlate With Previously Reported Gene Expression Profile Patterns in Plasma Cell Myeloma.
Mansoor A; Akhter A; Pournazari P; Mahe E; Shariff S; Farooq F; Elyamany G; Shahbani-Rad MT; Rashid-Kolvear F
Appl Immunohistochem Mol Morphol; 2015; 23(5):327-33. PubMed ID: 25265432
[TBL] [Abstract][Full Text] [Related]
32. [Molecular genetic methods for the prognostic criteria in multiple myeloma].
Mikala G; Jákó J; Vályi-Nagy I
Orv Hetil; 2005 Aug; 146(32):1673-82. PubMed ID: 16149245
[TBL] [Abstract][Full Text] [Related]
33. Relevance of Ras gene mutations in the context of the molecular heterogeneity of multiple myeloma.
Intini D; Agnelli L; Ciceri G; Ronchetti D; Fabris S; Nobili L; Lambertenghi-Deliliers G; Lombardi L; Neri A
Hematol Oncol; 2007 Mar; 25(1):6-10. PubMed ID: 17036375
[TBL] [Abstract][Full Text] [Related]
34. New insights into the pathophysiology of multiple myeloma.
Seidl S; Kaufmann H; Drach J
Lancet Oncol; 2003 Sep; 4(9):557-64. PubMed ID: 12965277
[TBL] [Abstract][Full Text] [Related]
35. Genetics of multiple myeloma.
Higgins MJ; Fonseca R
Best Pract Res Clin Haematol; 2005; 18(4):525-36. PubMed ID: 16026735
[TBL] [Abstract][Full Text] [Related]
36. Cyclin D1 positive multiple myeloma: predominance of the short, 3'UTR-deficient transcript is associated with high cyclin D1 mRNA levels in cases with t(11;14) translocation, but does not correlate with proliferation rate or genomic deletions.
Slotta-Huspenina J; Koch I; Richter M; Bink K; Kremer M; Specht K; Krugmann J; Quintanilla-Martinez L; Fend F
Leuk Res; 2008 Jan; 32(1):79-88. PubMed ID: 17629555
[TBL] [Abstract][Full Text] [Related]
37. Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype.
Rio-Machin A; Ferreira BI; Henry T; Gómez-López G; Agirre X; Alvarez S; Rodriguez-Perales S; Prosper F; Calasanz MJ; Martínez J; Fonseca R; Cigudosa JC
Leukemia; 2013 Apr; 27(4):925-31. PubMed ID: 23174883
[TBL] [Abstract][Full Text] [Related]
38. Frequent occurrence of CCND1 deregulation in patients with early stages of plasma cell dyscrasia.
Miura K; Iida S; Hanamura I; Kato M; Banno S; Ishida T; Kusumoto S; Takeuchi G; Miwa H; Nitta M; Inagaki H; Eimoto T; Nomura K; Taniwaki M; Ueda R
Cancer Sci; 2003 Apr; 94(4):350-4. PubMed ID: 12824903
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival.
Cook JR; Hsi ED; Worley S; Tubbs RR; Hussein M
Am J Clin Pathol; 2006 Apr; 125(4):615-24. PubMed ID: 16627271
[TBL] [Abstract][Full Text] [Related]
40. Quick detection of overexpressed genes caused by myeloma-specific chromosomal translocations using multiplex RT-PCR.
Htwe SS; Maeda M; Matsumoto R; Sakamoto N; Murakami S; Yamamoto S; Katoh M; Kumagai N; Hayashi H; Nishimura Y; Ohkura M; Wada H; Taniwaki M; Sugihara T; Otsuki T
Int J Mol Med; 2011 Jun; 27(6):789-94. PubMed ID: 21399865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
